Regulatory B Cells in Inflammatory Rheumatisms and Biomarkers of Response to Biologic Treatments

Study Overview
=================
Brief Summary
-----------------
B cells are known to play an important role in auto-immune diseases by activating T cells, secreting inflammatory cytokines and autoreactive antibodies. However, a sub-type of B cells named regulatory B cells or Bregs has recently shown capacities to prevent or cure arthritis in mouse models. Bregs have also been identified in humans.

Detailed Description
-----------------
B cells are known to play an important role in auto-immune diseases by activating T cells, secreting inflammatory cytokines and autoreactive antibodies. However, a sub-type of B cells named regulatory B cells or Bregs has recently shown capacities to prevent or cure arthritis in mouse models. Bregs have also been identified in humans. Main objective: To study Bregs abnormalities in patients with rheumatoid arthritis (RA) at different stages of the disease compared to subjects with mechanical pathologies.Secondary objectives:- To evaluate the specificity of any abnormalities identified in RA by studying Bregs in patients with other autoimmune or other inflammatory joint diseases.- To evaluate the effect of biological and synthetic treatments on Bregs in patients with RA. - To assess whether the rate of Bregs before treatment is predictive of response to biological and synthetic treatments.

Official Title
-----------------
Regulatory B Cells in Inflammatory Rheumatisms, Systemic Auto-immune Diseases in Adults and Biomarkers of Response to Biologic Treatments

Conditions
-----------------
Rheumatoid Arthritis, Osteoarthritis, Systemic Lupus Erythematosus, Sjogren's Syndrome, Scleroderma, Spondylitis, Gout, Spinal Disease, Chondrocalcinosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: For RA patients and control patients: Age over 18 year old Blood sample taken as part of the usual management Steroid less than or equal to 15 mg/day and stable for at least a week For RA patients: Patient with RA meeting the ACR / EULAR 2010 For control patients: Patients with systemic autoimmune disease (lupus, Sjogren's syndrome, scleroderma) or other inflammatory arthritis (spondylitis, crystals) or a mechanical pathology (limb osteoarthritis or spinal pathology) . Exclusion Criteria: steroids over 15 mg/day rituximab infusion in less than 12 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| RA patients<br>Patients affected by Rheumatoid arthritis. | |
| Control<br>Subjects affected by either : mechanical pathology systemic auto-immune pathology other inflammatory rheumatism | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of Bregs levels | The levels of Bregs will be assessed in patients with RA and compared to subjects with mechanical pathologies. | 30 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of Bregs levels after therapy | The levels of Bregs will be assessed in patients who will start a therapy within the framework of their usual follow-up. | 30 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Regulatory B cells, Rheumatoid arthritis, Biomarker